Genotypic antiretroviral resistance testing for human immunodeficiency virus type 1 integrase inhibitors by use of the TruGene sequencing system

Journal of Clinical Microbiology

Volumn 46, Issue 12, 2008, Pages 4087-4090

  Paar, Christian ^a   Palmetshofer, Christina ^a   Flieger, Karin ^b,d   Geit, Maria ^a   Kaiser, Rolf ^c   Stekel, Herbert ^a   Berg, Jörg ^a  

^a KEPLER UNIVERSITY HOSPITAL   (Austria)

^b SIEMENS AG   (Germany)

^c UNIVERSITY OF COLOGNE   (Germany)

^d Leica Biosystems Nussloch GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ELVITEGRAVIR; RALTEGRAVIR; RNA;

ARTICLE; CONTROLLED STUDY; DRUG SCREENING; GENE MUTATION; GENE SEQUENCE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; LABORATORY AUTOMATION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; VIRUS RESISTANCE;

AMINO ACID SUBSTITUTION; GENOTYPE; HIV-1; HUMANS; INTEGRASE INHIBITORS; MICROBIAL SENSITIVITY TESTS; MUTATION, MISSENSE; RNA, VIRAL; SEQUENCE ANALYSIS, DNA;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 57349198266     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.01246-08     Document Type: Article

References (16)

1. Beerenwinkel, N., T. Sing, T. Lengauer, J. Rahnenführer, K. Roomp, I. Savenkov, R. Fischer, D. Hoffmann, J. Selbig, K. Korn, H. Walter, T. Berg, P. Braun, G. Fätkenheuer, M. Oette, J. Rockstroh, B. Kupfer, R. Kaiser, and M. Däumer. 2005. Computational methods for the design of effective therapies against drug resistant HIV strains. Bioinformatics 21:3943-3950.
2. Department of Health and Human Services. 2008. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.
3. Erali, M., S. Page, L. G. Reimer, and D. R. Hillyard. 2001. Human immunodeficiency virus type 1 drug resistance testing: a comparison of three sequence-based methods. J. Clin. Microbiol. 39:2157-2165.
4. Gale, H. B., V. L. Kan, And R. C. Shinol. 2006. Performance of the TruGene human immunodeficiency virus type 1 genotyping kit and the OpenGene DNA sequencing system on clinical samples diluted to approximately 100 copies per milliliter. Clin. Vaccine Immunol. 13:235-238.
5. Grant, R. M., D. R. Kuritzkes, V. A. Johnson, J. W. Mellors, J. L. Sulivan, R. Swanstorm, R. T. D'Auila, M. van Gorder, M Holodniy, R. M. Lloyd, Jr., C. Reid, G. F. Morgan, and D. L. Winslow. 2003. Accuracy of the TRUGENE HIV-1 genotyping kit. J. Clin. Microbiol. 41:1586-1593.
6. Hirsch, M. S., H. F. Günthard, J. M. Schapiro. F. Brun-Vézinet, B. Clotet, S. M. Hammer, V. A. Johnson, D. R. Kuritzkes, J. W. Mellors, D. Pillay, P. G. Yeni, D. M. Jacobson, and D. D. Richman. 2008. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an international AIDS society-USA panel. Clin. Infect. Dis. 47:266-285.
7. Hölzl, G., M. Stöcher, V. Leb, H. Stekel, and J. Berg. 2003. Entirely automated quantification of human immunodeficiency virus type 1 (HIV-1) RNA in plasma by using the ultrasensitive COBAS AMPLICOR HIV-1 monitor test and RNA purification on the MagNA pure LC instrument. J. Clin. Microbiol. 41:1248-1251.
8. Jagodzinski, L. L., J. D. Cooley, M. Weber, and N. L. Michael. 2003. Performance characteristics of human immunodeficiency virus type 1 (HIV-1) genotyping system in sequence-based analysis of subtypes other than HIV-1 subtype B. J. Clin. Microbiol. 41:998-1003.
9. Kuritzkes, D. R., R. M. Grant, P. Feorino, M. Griswold, M. Hoover, R. Young, S. Day, R. M. Lloyd, Jr., C. Reid, G. F. Morgan, and D. L. Winslow. 2003. Performance characteristics of the TRUGENE HIV-1 genotyping kit and the OpenGene DNA sequencing system. J. Clin. Microbiol. 41:1594-1599.
10. Lataillade, M., J. Chiarella, and M. J. Kozal. 2007. Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance. Antivir. Ther. 12:563-570.
11. Malet, I., O. Delelis, M.-A. Valantin, B. Montes, C. Soulie, M. Wirden, L. Tchertanov, G. Peytavin, J. Reynes, J.-F. Mouscadet, C. Katlama, V. Calvez, and A.-G. Marcelin. 2008. Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro. Antimicrob. Agents Chemother. 52:1351-1358.
12. Murphy, E. L., A. C. Collier, L. A. Kalish, S. F. Assamnn, M. F. Para, T. P. Flanigan, P. N. Kumar, L. Mintz, F. R. Wallach, and G. J. Nemo. 2001. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann. Intern. Med. 135:17-26.
13. Pommier, Y., A. A. Johnson, and C. Marchand. 2005. Integrase inhibitors to treat HIV/AIDS. Nat. Rev. Drug Discov. 4:236-248.
14. Rozanov, M., U. Pilkat, C. Chappey, A. Kochergin, and T. Tatusova. 2004. A web-based genotyping resource for viral sequences. Nucleic Acids Res. 32:W654-W659.
15. Semenova, E. A., C. Marchand, and Y. Pommier. 2008. HIV-1 integrase inhibitors: update and perspectives. Adv. Pharmacol. 56:159-228.
16. Shimura, K., E. Kodama, Y. Sakagami, Y. Matsuzaki, W. Watanabe, K. Yamataka, Y. Watanabe, Y. Ohata, S. Doi, M. Sato, M. Kano, S. Ikeda, and M. Matsuoka. 2008. Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137). J. Virol. 82:764-774.